Results 191 to 200 of about 357,374 (264)

Long pedunculated tumor from the ureteral stump protruding into the bladder after nephrectomy: a case report. [PDF]

Discov Oncol
Li J, Guo J, Huang J, Wu Q, Huang J.
europepmc   +1 more source

Variations in Treatment Prescription and Survival Outcomes Between Older and Younger Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Radiotherapy

Head &Neck, EarlyView.
ABSTRACT Purpose To investigate treatment variations and outcomes between older (≥ 70 years) and younger (< 70 years) patients with mucosal head and neck squamous cell carcinoma (mHNSCC) treated with radiotherapy. Methods A multicenter retrospective review of patients diagnosed from 2010 to 2018 was conducted.
Farhannah Aly, Joseph Descallar, Purnima Sundaresan, Alexis Andrew Miller, Lois Holloway, Shalini Vinod   +5 more
wiley   +1 more source

Invasive Renal Parenchymal Urothelial Carcinoma: A Case Report and Literature Review of Imaging Features and Spectrum of Infiltrative Renal Masses. [PDF]

Cureus
Loughraieb S, Guendouzi R, Terki F, Mokeddem K, Aimeur C.   +4 more
europepmc   +1 more source

miR-1251-5p inhibits tumorigenesis and metastasis in renal cell carcinoma by targeting MTHFD2. [PDF]

Transl Androl Urol
Li Y, Fan G, Wang G, He H.
europepmc   +1 more source

Pathological Complete Response to Nivolumab Plus Ipilimumab Combination Therapy in Advanced Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus. [PDF]

IJU Case Rep
Tsuchiya T, Kimura G, Takeda H, Akatsuka J, Hasegawa H, Toyama Y, Sakatani T, Shimizu A, Ohashi R, Kondo Y.   +9 more
europepmc   +1 more source

Proliferation Cinetics and Prognosis of Renal Cell Carcinoma [PDF]

, 1991
Werner, M., Stief, Christian Georg, Riese, W. de, Azpodien, J., Kirchner, H., Allhoff, E. P.   +5 more
core  

Reply to the Letter to the Editor: Diagnostic performance of the clear cell likelihood score integrated with cystic degeneration or necrosis on MR imaging for identifying clear cell renal cell carcinoma in cT1 solid renal masses. [PDF]

Insights Imaging
Ning X, Wang H.
europepmc   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, EarlyView.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source

Last Licensed Non-Classical Peptide Presenter HLA-F: Its Occurrence, Immunoediting Significance, and Possible Therapeutic Implications in Renal Cell Carcinoma. [PDF]

Int J Mol Sci
Janků L, Fedorko M, Kašík M, Macháčková T, Křen L.   +4 more
europepmc   +1 more source

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle‐Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab‐Gemcitabine‐Cisplatin Versus Gemcitabine‐Cisplatin: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials

International Journal of Cancer, EarlyView.
Optimizing neoadjuvant therapy for muscle‐invasive bladder cancer patients who are eligible for cisplatin remains difficult, owing particularly to high toxicity and recurrence rates. This meta‐analysis compared dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) against durvalumab plus gemcitabine‐cisplatin (D‐GC) and GC alone ...
Maurin Helen Mangold, Gloria Baumann, Victoria Luise Simone Wieland, Nicolas Carl, Luisa Vivienne Renner, Alexander Studier‐Fischer, Hanna Menold, Stefanie Zschäbitz, Frederik Wessels, Niklas Westhoff, Maurice Stephan Michel, Karl‐Friedrich Kowalewski, Caelán Max Haney‐Aubert   +12 more
wiley   +1 more source